# PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC

> **NCT07645222** · PHASE1 · RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 396 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** HS-20122+Aumolertinib
- **DRUG:** HS-20122+Adbrelimab
- **DRUG:** HS-20122+Adbrelimab+Platinum-based Chemo

## Key facts

- **NCT ID:** NCT07645222
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2028-10-31
- **Final completion:** 2029-04-30
- **Target enrollment:** 396 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07645222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07645222, "PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07645222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*